Lv1
93 积分 2021-05-06 加入
T cell-based cancer immunotherapy: opportunities and challenges
24天前
已完结
Characterisation and outcome of RAC1 mutated melanoma
1个月前
已完结
T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics
1个月前
已完结
Harnessing the Power of TCR-T Cell Therapy: A New Era in Cancer Immunotherapy
1个月前
已完结
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
2个月前
已完结
BET proteins: Biological functions and therapeutic interventions
2个月前
已完结
Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting
2个月前
已关闭
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma
3个月前
已完结
Risk of HBV reactivation during therapies for HCC: A systematic review
3个月前
已完结
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial
4个月前
已完结
皖公网安备34019202002308
